The antimalarial amodiaquine causes autophagic-lysosomal and proliferative blockade sensitizing human melanoma cells to starvation- And chemotherapy-induced cell death

Autophagy

Volumn 9, Issue 12, 2013, Pages 2087-2102

  Qiao, Shuxi ^a   Tao, Shasha ^a   Rojo De La Vega, Montserrat ^a   Park, Sophia L ^a   Vonderfecht, Amanda A ^a   Jacobs, Suesan L ^a   Zhang, Donna D ^a   Wondrak, Georg T ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

Amodiaquine; Autophagy; Cathepsin; CDKN1A; Chloroquine; E2F1; Lysosome; Malignant melanoma

Indexed keywords

AMODIAQUINE; CATHEPSIN; CATHEPSIN B; CYCLIN DEPENDENT KINASE INHIBITOR 1A; LC3 II PROTEIN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; PROTEIN P53; SQSTM1 PROTEIN; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; AUTOLYSOSOME; AUTOPHAGY; CELL DEATH; CONTROLLED STUDY; ELECTRON MICROSCOPY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MELANOMA; MELANOMA CELL; MICROSCOPY; NUCLEOTIDE SEQUENCE; POLYACRYLAMIDE GEL ELECTROPHORESIS; S PHASE CELL CYCLE CHECKPOINT; TRANSMISSION ELECTRON MICROSCOPY;

AMODIAQUINE; AUTOPHAGY; CATHEPSIN; CDKN1A; CHLOROQUINE; E2F1; LYSOSOME; MALIGNANT MELANOMA;

AMODIAQUINE; ANTIMALARIALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUTOPHAGY; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; ENERGY METABOLISM; HUMANS; LYSOSOMES; MELANOMA;

EID: 84890810356     PISSN: 15548627     EISSN: 15548635     Source Type: Journal    
DOI: 10.4161/auto.26506     Document Type: Article

References (92)

1. Klionsky DJ. Autophagy: from phenomenology to molecular understanding in less than a decade. Nat Rev Mol Cell Biol 2007; 8:931-7; PMID:17712358; http://dx.doi.org/10.1038/nrm2245
2. Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease through cellular self-digestion. Nature 2008; 451:1069-75; PMID:18305538; http://dx.doi.org/10.1038/nature06639
3. Cecconi F, Levine B. The role of autophagy in mammalian development: cell makeover rather than cell death. Dev Cell 2008; 15:344-57; PMID:18804433; http://dx.doi.org/10.1016/j.devcel.2008.08.012
4. Rubinsztein DC, Codogno P, Levine B. Autophagy modulation as a potential therapeutic target for diverse diseases. Nat Rev Drug Discov 2012; 11:709-30; PMID:22935804; http://dx.doi.org/10.1038/nrd3802
5. Benbrook DM, Long A. Integration of autophagy, proteasomal degradation, unfolded protein response and apoptosis. Exp Oncol 2012; 34:286-97; PMID:23070014
6. Lau A, Zheng Y, Tao S, Wang H, Whitman SA, White E, Zhang DD. Arsenic inhibits autophagic flux, activating the Nrf2-Keap1 pathway in a p62-dependent manner. Mol Cell Biol 2013; 33:2436-46; PMID:23589329; http://dx.doi.org/10. 1128/MCB.01748-12
7. Lamore SD, Wondrak GT. Autophagic-lysosomal dysregulation downstream of cathepsin B inactivation in human skin fibroblasts exposed to UVA. Photochem Photobiol Sci 2012; 11:163-72; PMID:21773629; http://dx.doi.org/10.1039/ c1pp05131h
8. Lamore SD, Wondrak GT. UVA causes dual inactivation of cathepsin B and L underlying lysosomal dysfunction in human dermal fibroblasts. J Photochem Photobiol B 2013; 123:1-12; PMID:23603447; http://dx.doi.org/10.1016/j. jphotobiol.2013.03.007
9. Amaravadi RK, Lippincott-Schwartz J, Yin XM, Weiss WA, Takebe N, Timmer W, DiPaola RS, Lotze MT, White E. Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res 2011; 17:654-66; PMID:21325294; http://dx.doi.org/10.1158/1078-0432.CCR-10-2634
10. Sheen JH, Zoncu R, Kim D, Sabatini DM. Defective regulation of autophagy upon leucine deprivation reveals a targetable liability of human melanoma cells in vitro and in vivo. Cancer Cell 2011; 19:613-28; PMID:21575862; http://dx.doi.org/10.1016/j.ccr.2011.03.012
11. Yu H, Su J, Xu Y, Kang J, Li H, Zhang L, Yi H, Xiang X, Liu F, Sun L. p62/SQSTM1 involved in cisplatin resistance in human ovarian cancer cells by clearing ubiquitinated proteins. Eur J Cancer 2011; 47:1585-94; PMID:21371883; http://dx.doi.org/10.1016/j.ejca.2011.01.019
12. O'Donovan TR, O'Sullivan GC, McKenna SL. Induction of autophagy by drug-resistant esophageal cancer cells promotes their survival and recovery following treatment with chemotherapeutics. Autophagy 2011; 7:509-24; PMID:21325880; http://dx.doi.org/10.4161/auto.7.5.15066
13. Amaravadi RK, Yu D, Lum JJ, Bui T, Christophorou MA, Evan GI, Thomas-Tikhonenko A, Thompson CB. Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest 2007; 117:326-36; PMID:17235397; http://dx.doi.org/10.1172/JCI28833
14. Degtyarev M, De Mazière A, Klumperman J, Lin K. Autophagy, an Achilles' heel AKTing against cancer? Autophagy 2009; 5:415-8; PMID:19305139; http://dx.doi.org/10.4161/auto.5.3.7827
15. Xie X, White EP, Mehnert JM. Coordinate autophagy and mTOR pathway inhibition enhances cell death in melanoma. PLoS One 2013; 8:e55096; PMID:23383069; http://dx.doi.org/10.1371/journal.pone.0055096
16. Reaume AG. Drug repurposing through nonhypothesis driven phenotypic screening. Drug Discov Today 2011; 8:85-8
17. Weir SJ, DeGennaro LJ, Austin CP. Repurposing approved and abandoned drugs for the treatment and prevention of cancer through public-private partnership. Cancer Res 2012; 72:1055-8; PMID:22246671; http://dx.doi.org/10. 1158/0008-5472.CAN-11-3439
18. Neznanov N, Gorbachev AV, Neznanova L, Komarov AP, Gurova KV, Gasparian AV, Banerjee AK, Almasan A, Fairchild RL, Gudkov AV. Antimalaria drug blocks proteotoxic stress response: anti-cancer implications. Cell Cycle 2009; 8:3960-70; PMID:19901558; http://dx.doi.org/10.4161/cc.8.23.10179
19. Garber K. Inducing indigestion: companies embrace autophagy inhibitors. J Natl Cancer Inst 2011; 103:708-10; PMID:21515831; http://dx.doi.org/10.1093/ jnci/djr168
20. Sharma N, Thomas S, Golden EB, Hofman FM, Chen TC, Petasis NA, Schönthal AH, Louie SG. Inhibition of autophagy and induction of breast cancer cell death by mefloquine, an antimalarial agent. Cancer Lett 2012; 326:143-54; PMID:22863539; http://dx.doi.org/10.1016/j.canlet.2012.07.029
21. Solomon VR, Lee H. Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies. Eur J Pharmacol 2009; 625:220-33; PMID:19836374; http://dx.doi.org/10.1016/j.ejphar.2009.06.063
22. Sukhai MA, Prabha S, Hurren R, Rutledge AC, Lee AY, Sriskanthadevan S, Sun H, Wang X, Skrtic M, Seneviratne A, et al. Lysosomal disruption preferentially targets acute myeloid leukemia cells and progenitors. J Clin Invest 2013; 123:315-28; PMID:23202731; http://dx.doi.org/10.1172/JCI64180
23. Bristol ML, Emery SM, Maycotte P, Thorburn A, Chakradeo S, Gewirtz DA. Autophagy inhibition for chemosensitization and radiosensitization in cancer: do the preclinical data support this therapeutic strategy? J Pharmacol Exp Ther 2013; 344:544-52; PMID:23291713; http://dx.doi.org/10.1124/jpet.112.199802
24. Kimura T, Takabatake Y, Takahashi A, Isaka Y. Chloroquine in cancer therapy: a double-edged sword of autophagy. Cancer Res 2013; 73:3-7; PMID:23288916; http://dx.doi.org/10.1158/0008-5472.CAN-12-2464
25. Garbe C, Eigentler TK, Keilholz U, Hauschild A, Kirkwood JM. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 2011; 16:5-24; PMID:21212434; http://dx.doi.org/10.1634/ theoncologist.2010-0190
26. Ibrahim N, Haluska FG. Molecular pathogenesis of cutaneous melanocytic neoplasms. Annu Rev Pathol 2009; 4:551-79; PMID:19400696; http://dx.doi.org/10. 1146/annurev.pathol.3.121806.151541
27. Aplin AE, Kaplan FM, Shao Y. Mechanisms of resistance to RAF inhibitors in melanoma. J Invest Dermatol 2011; 131:1817-20; PMID:21593776; http://dx.doi.org/10.1038/jid.2011.147
28. Armstrong JL, Corazzari M, Martin S, Pagliarini V, Falasca L, Hill DS, Ellis N, Al Sabah S, Redfern CP, Fimia GM, et al. Oncogenic B-RAF signaling in melanoma impairs the therapeutic advantage of autophagy inhibition. Clin Cancer Res 2011; 17:2216-26; PMID:21270111; http://dx.doi.org/10.1158/1078-0432.CCR-10- 3003
29. Marino ML, Pellegrini P, Di Lernia G, Djavaheri-Mergny M, Brnjic S, Zhang X, Hägg M, Linder S, Fais S, Codogno P, et al. Autophagy is a protective mechanism for human melanoma cells under acidic stress. J Biol Chem 2012; 287:30664-76; PMID:22761435; http://dx.doi.org/10.1074/jbc.M112.339127
30. Ma XH, Piao S, Wang D, McAfee QW, Nathanson KL, Lum JJ, Li LZ, Amaravadi RK. Measurements of tumor cell autophagy predict invasiveness, resistance to chemotherapy, and survival in melanoma. Clin Cancer Res 2011; 17:3478-89; PMID:21325076; http://dx.doi.org/10.1158/1078-0432.CCR-10-2372
31. Flemming A. Cancer: Autophagy presents Achilles heel in melanoma. Nat Rev Drug Discov 2011; 10:491; PMID:21720400; http://dx.doi.org/10.1038/nrd3482
32. Del Bello B, Toscano M, Moretti D, Maellaro E. Cisplatin-induced apoptosis inhibits autophagy, which acts as a pro-survival mechanism in human melanoma cells. PLoS One 2013; 8:e57236; PMID:23437349; http://dx.doi.org/10. 1371/journal.pone.0057236
33. rd, Qiao S, Azimian S, Lesson JL, Wondrak GT. The redox antimalarial dihydroartemisinin targets human metastatic melanoma cells but not primary melanocytes with induction of NOXA-dependent apoptosis. Invest New Drugs 2012; 30:1289-301; PMID:21547369; http://dx.doi.org/10.1007/s10637-011-9676-7
34. Wondrak GT. Redox-directed cancer therapeutics: molecular mechanisms and opportunities. Antioxid Redox Signal 2009; 11:3013-69; PMID:19496700; http://dx.doi.org/10.1089/ars.2009.2541
35. Eastman RT, Fidock DA. Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. Nat Rev Microbiol 2009; 7:864-74; PMID:19881520
36. Anvikar AR, Sharma B, Shahi BH, Tyagi PK, Bose TK, Sharma SK, Srivastava P, Srivastava B, Kiechel JR, Dash AP, et al. Artesunate-amodiaquine fixed dose combination for the treatment of Plasmodium falciparum malaria in India. Malar J 2012; 11:97; PMID:22458860; http://dx.doi.org/10.1186/1475-2875-11-97
37. Lamore SD, Azimian S, Horn D, Anglin BL, Uchida K, Cabello CM, Wondrak GT. The malondialdehyde-derived fluorophore DHP-lysine is a potent sensitizer of UVA-induced photooxidative stress in human skin cells. J Photochem Photobiol B 2010; 101:251-64; PMID:20724175; http://dx.doi.org/10.1016/j.jphotobiol.2010.07. 010
38. Lamore SD, Qiao S, Horn D, Wondrak GT. Proteomic identification of cathepsin B and nucleophosmin as novel UVA-targets in human skin fibroblasts. Photochem Photobiol 2010; 86:1307-17; PMID:20946361; http://dx.doi.org/10.1111/ j.1751-1097.2010.00818.x
39. Eskelinen E-L. Roles of LAMP-1 and LAMP-2 in lysosome biogenesis and autophagy. Mol Aspects Med 2006; 27:495-502; PMID:16973206; http://dx.doi.org/ 10.1016/j.mam.2006.08.005
40. Mizushima N, Yoshimori T. How to interpret LC3 immunoblotting. Autophagy 2007; 3:542-5; PMID:17611390
41. Ichimura Y, Kominami E, Tanaka K, Komatsu M. Selective turnover of p62/A170/SQSTM1 by autophagy. Autophagy 2008; 4:1063-6; PMID:18776737
42. Johansen T, Lamark T. Selective autophagy mediated by autophagic adapter proteins. Autophagy 2011; 7:279-96; PMID:21189453; http://dx.doi.org/10.4161/ auto.7.3.14487
43. Pankiv S, Clausen TH, Lamark T, Brech A, Bruun JA, Outzen H, Øvervatn A, Bjørkøy G, Johansen T. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J Biol Chem 2007; 282:24131-45; PMID:17580304; http://dx.doi.org/10.1074/jbc.M702824200
44. Kabuta T, Furuta A, Aoki S, Furuta K, Wada K. Aberrant interaction between Parkinson disease-associated mutant UCH-L1 and the lysosomal receptor for chaperone-mediated autophagy. J Biol Chem 2008; 283:23731-8; PMID:18550537; http://dx.doi.org/10.1074/jbc.M801918200
45. Sevlever D, Jiang P, Yen SH. Cathepsin D is the main lysosomal enzyme involved in the degradation of alpha-synuclein and generation of its carboxy-terminally truncated species. Biochemistry 2008; 47:9678-87; PMID:18702517; http://dx.doi.org/10.1021/bi800699v
46. Wang J. Beclin 1 bridges autophagy, apoptosis and differentiation. Autophagy 2008; 4:947-8; PMID:18769161
47. Maggs JL, Tingle MD, Kitteringham NR, Park BK. Drug-protein conjugates - XIV. Mechanisms of formation of protein-arylating intermediates from amodiaquine, a myelotoxin and hepatotoxin in man. Biochem Pharmacol 1988; 37:303-11; PMID:3342086; http://dx.doi.org/10.1016/0006-2952(88)90733-2
48. Tafazoli S, O'Brien PJ. Amodiaquine-induced oxidative stress in a hepatocyte inflammation model. Toxicology 2009; 256:101-9; PMID:19059302; http://dx.doi.org/10.1016/j.tox.2008.11.006
49. Mizushima N, Yoshimori T, Levine B. Methods in mammalian autophagy research. Cell 2010; 140:313-26; PMID:20144757; http://dx.doi.org/10.1016/j. cell.2010.01.028
50. Yamamoto A, Tagawa Y, Yoshimori T, Moriyama Y, Masaki R, Tashiro Y. Bafilomycin A1 prevents maturation of autophagic vacuoles by inhibiting fusion between autophagosomes and lysosomes in rat hepatoma cell line, H-4-II-E cells. Cell Struct Funct 1998; 23:33-42; PMID:9639028; http://dx.doi.org/10.1247/csf. 23.33
51. Marceau F, Bawolak MT, Lodge R, Bouthillier J, Gagné-Henley A, Gaudreault RC, Morissette G. Cation trapping by cellular acidic compartments: beyond the concept of lysosomotropic drugs. Toxicol Appl Pharmacol 2012; 259:1-12; PMID:22198553; http://dx.doi.org/10.1016/j.taap.2011.12.004
52. Homewood CA, Warhurst DC, Peters W, Baggaley VC. Lysosomes, pH and the anti-malarial action of chloroquine. Nature 1972; 235:50-2; PMID:4550396; http://dx.doi.org/10.1038/235050a0
53. Slater AF. Chloroquine: mechanism of drug action and resistance in Plasmodium falciparum. Pharmacol Ther 1993; 57:203-35; PMID:8361993; http://dx.doi.org/10.1016/0163-7258(93)90056-J
54. Koike M, Shibata M, Waguri S, Yoshimura K, Tanida I, Kominami E, Gotow T, Peters C, von Figura K, Mizushima N, et al. Participation of autophagy in storage of lysosomes in neurons from mouse models of neuronal ceroid-lipofuscinoses (Batten disease). Am J Pathol 2005; 167:1713-28; PMID:16314482; http://dx.doi.org/10.1016/S0002-9440(10)61253-9
55. Ha SD, Ham B, Mogridge J, Saftig P, Lin S, Kim SO. Cathepsin B-mediated autophagy flux facilitates the anthrax toxin receptor 2-mediated delivery of anthrax lethal factor into the cytoplasm. J Biol Chem 2010; 285:2120-9; PMID:19858192; http://dx.doi.org/10.1074/jbc.M109.065813
56. Boya P, Gonzalez-Polo RA, Poncet D, Andreau K, Vieira HL, Roumier T, Perfettini JL, Kroemer G. Mitochondrial membrane permeabilization is a critical step of lysosome-initiated apoptosis induced by hydroxychloroquine. Oncogene 2003; 22:3927-36; PMID:12813466; http://dx.doi.org/10.1038/sj.onc.1206622
57. Fantin VR, Berardi MJ, Scorrano L, Korsmeyer SJ, Leder P. A novel mitochondriotoxic small molecule that selectively inhibits tumor cell growth. Cancer Cell 2002; 2:29-42; PMID:12150823; http://dx.doi.org/10.1016/S1535- 6108(02)00082-X
58. Fantin VR, Leder P. Mitochondriotoxic compounds for cancer therapy. Oncogene 2006; 25:4787-97; PMID:16892091; http://dx.doi.org/10.1038/sj.onc. 1209599
59. rd, Davis AL, Azimian SM, Wondrak GT. DCPIP (2,6-dichlorophenolindophenol) as a genotype-directed redox chemotherapeutic targeting NQO1*2 breast carcinoma. Free Radic Res 2011; 45:276-92; PMID:21034357; http://dx.doi.org/10.3109/10715762.2010.526766
60. Gartel AL, Radhakrishnan SK. Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res 2005; 65:3980-5; PMID:15899785; http://dx.doi.org/10.1158/0008-5472.CAN-04-3995
61. Davis AL, Cabello CM, Qiao S, Azimian S, Wondrak GT. Phenotypic identification of the redox dye methylene blue as an antagonist of heat shock response gene expression in metastatic melanoma cells. Int J Mol Sci 2013; 14:4185-202; PMID:23429201; http://dx.doi.org/10.3390/ijms14024185
62. Qiao S, Lamore SD, Cabello CM, Lesson JL, Muñoz-Rodriguez JL, Wondrak GT. Thiostrepton is an inducer of oxidative and proteotoxic stress that impairs viability of human melanoma cells but not primary melanocytes. Biochem Pharmacol 2012; 83:1229-40; PMID:22321511; http://dx.doi.org/10.1016/j.bcp.2012. 01.027
63. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009; 136:823-37; PMID:19269363; http://dx.doi.org/10.1016/j.cell.2009.02.024
64. Qiao S, Cabello CM, Lamore SD, Lesson JL, Wondrak GT. D-Penicillamine targets metastatic melanoma cells with induction of the unfolded protein response (UPR) and Noxa (PMAIP1)-dependent mitochondrial apoptosis. Apoptosis 2012; 17:1079-94; PMID:22843330; http://dx.doi.org/10.1007/s10495-012-0746-x
65. rd, Ley S, Lamore SD, Azimian S, Wondrak GT. The experimental chemotherapeutic N6-furfuryladenosine (kinetinriboside) induces rapid ATP depletion, genotoxic stress, and CDKN1A(p21) upregulation in human cancer cell lines. Biochem Pharmacol 2009; 77:1125-38; PMID:19186174; http://dx.doi.org/10.1016/j.bcp.2008.12.002
66. Warfel NA, El-Deiry WS. p21WAF1 and tumourigenesis: 20 years after. Curr Opin Oncol 2013; 25:52-8; PMID:23159848; http://dx.doi.org/10.1097/CCO. 0b013e32835b639e
67. Ma Y, Kurtyka CA, Boyapalle S, Sung SS, Lawrence H, Guida W, Cress WD. A small-molecule E2F inhibitor blocks growth in a melanoma culture model. Cancer Res 2008; 68:6292-9; PMID:18676853; http://dx.doi.org/10.1158/0008-5472.CAN-08- 0121
68. DeGregori J, Johnson DG. Distinct and Overlapping Roles for E2F Family Members in Transcription, Proliferation and Apoptosis. Curr Mol Med 2006; 6:739-48; PMID:17100600
69. Biswas AK, Johnson DG. Transcriptional and nontranscriptional functions of E2F1 in response to DNA damage. Cancer Res 2012; 72:13-7; PMID:22180494; http://dx.doi.org/10.1158/0008-5472.CAN-11-2196
70. Samant GV, Wali VB, Sylvester PW. Antiproliferative effects of gamma-tocotrienol on mammary tumour cells are associated with suppression of cell cycle progression. Cell Prolif 2010; 43:77-83; PMID:19922488; http://dx.doi.org/10.1111/j.1365-2184.2009.00657.x
71. Macdonald JI, Dick FA. Posttranslational modifications of the retinoblastoma tumor suppressor protein as determinants of function. Genes Cancer 2012; 3:619-33; PMID:23634251; http://dx.doi.org/10.1177/1947601912473305
72. Wibo M, Poole B. Protein degradation in cultured cells. II. The uptake of chloroquine by rat fibroblasts and the inhibition of cellular protein degradation and cathepsin B1. J Cell Biol 1974; 63:430-40; PMID:4607946; http://dx.doi.org/10.1083/jcb.63.2.430
73. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012; 8:445-544; PMID:22966490; http://dx.doi.org/10.4161/auto.19496
74. Maclean KH, Dorsey FC, Cleveland JL, Kastan MB. Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis. J Clin Invest 2008; 118:79-88; PMID:18097482; http://dx.doi.org/10.1172/JCI33700
75. Zhu H, Zhang L, Wu S, Teraishi F, Davis JJ, Jacob D, Fang B. Induction of S-phase arrest and p21 overexpression by a small molecule 2[[3-(2,3- dichlorophenoxy) propyl] amino]ethanol in correlation with activation of ERK. Oncogene 2004; 23:4984-92; PMID:15122344; http://dx.doi.org/10.1038/sj.onc. 1207645
76. Ogryzko VV, Wong P, Howard BH. WAF1 retards S-phase progression primarily by inhibition of cyclin-dependent kinases. Mol Cell Biol 1997; 17:4877-82; PMID:9234744
77. Joe AK, Liu H, Suzui M, Vural ME, Xiao D, Weinstein IB. Resveratrol induces growth inhibition, S-phase arrest, apoptosis, and changes in biomarker expression in several human cancer cell lines. Clin Cancer Res 2002; 8:893-903; PMID:11895924
78. Knudsen KE, Booth D, Naderi S, Sever-Chroneos Z, Fribourg AF, Hunton IC, Feramisco JR, Wang JY, Knudsen ES. RB-dependent S-phase response to DNA damage. Mol Cell Biol 2000; 20:7751-63; PMID:11003670; http://dx.doi.org/10.1128/MCB.20. 20.7751-7763.2000
79. Hockenbery DM. Targeting mitochondria for cancer therapy. Environ Mol Mutagen 2010; 51:476-89; PMID:20213841; http://dx.doi.org/10.1002/em.20552
80. Maycotte P, Aryal S, Cummings CT, Thorburn J, Morgan MJ, Thorburn A. Chloroquine sensitizes breast cancer cells to chemotherapy independent of autophagy. Autophagy 2012; 8:200-12; PMID:22252008; http://dx.doi.org/10.4161/ auto.8.2.18554
81. Neckers L, Workman P. Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res 2012; 18:64-76; PMID:22215907; http://dx.doi.org/10.1158/ 1078-0432.CCR-11-1000
82. Wang RE. Targeting heat shock proteins 70/90 and proteasome for cancer therapy. Curr Med Chem 2011; 18:4250-64; PMID:21838681; http://dx.doi.org/10. 2174/092986711797189574
83. Ochong EO, van den Broek IV, Keus K, Nzila A. Short report: association between chloroquine and amodiaquine resistance and allelic variation in the Plasmodium falciparum multiple drug resistance 1 gene and the chloroquine resistance transporter gene in isolates from the upper Nile in southern Sudan. Am J Trop Med Hyg 2003; 69:184-7; PMID:13677373
84. Famin O, Ginsburg H. Differential effects of 4-aminoquinoline-containing antimalarial drugs on hemoglobin digestion in Plasmodium falciparum-infected erythrocytes. Biochem Pharmacol 2002; 63:393-8; PMID:11853690; http://dx.doi.org/10.1016/S0006-2952(01)00878-4
85. Obua C, Gustafsson LL, Aguttu C, Anokbonggo WW, Ogwal-Okeng JW, Chiria J, Hellgren U. Improved efficacy with amodiaquine instead of chloroquine in sulfadoxine/pyrimethamine combination treatment of falciparum malaria in Uganda: experience with fixed-dose formulation. Acta Trop 2006; 100:142-50; PMID:17113554; http://dx.doi.org/10.1016/j.actatropica.2006.10.007
86. Hawley SR, Bray PG, Park BK, Ward SA. Amodiaquine accumulation in Plasmodium falciparum as a possible explanation for its superior antimalarial activity over chloroquine. Mol Biochem Parasitol 1996; 80:15-25; PMID:8885219; http://dx.doi.org/10.1016/0166-6851(96)02655-2
87. Mirković B, Sosič I, Gobec S, Kos J. Redox-based inactivation of cysteine cathepsins by compounds containing the 4-aminophenol moiety. PLoS One 2011; 6:e27197; PMID:22073285; http://dx.doi.org/10.1371/ journal.pone.0027197
88. Parikh S, Ouedraogo JB, Goldstein JA, Rosenthal PJ, Kroetz DL. Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa. Clin Pharmacol Ther 2007; 82:197-203; PMID:17361129; http://dx.doi.org/10.1038/sj.clpt.6100122
89. Roederer MW, McLeod H, Juliano JJ. Can pharmacogenomics improve malaria drug policy? Bull World Health Organ 2011; 89:838-45; PMID:22084530; http://dx.doi.org/10.2471/BLT.11.087320
90. Lamore SD, Cabello CM, Wondrak GT. The topical antimicrobial zinc pyrithione is a heat shock response inducer that causes DNA damage and PARP-dependent energy crisis in human skin cells. Cell Stress Chaperones 2010; 15:309-22; PMID:19809895; http://dx.doi.org/10.1007/s12192-009-0145-6
91. Werle B, Ebert W, Klein W, Spiess E. Assessment of cathepsin L activity by use of the inhibitor CA-074 compared to cathepsin B activity in human lung tumor tissue. Biol Chem Hoppe Seyler 1995; 376:157-64; PMID:7612192; http://dx.doi.org/10.1515/bchm3.1995.376.3.157
92. Levicar N, Dewey RA, Daley E, Bates TE, Davies D, Kos J, Pilkington GJ, Lah TT. Selective suppression of cathepsin L by antisense cDNA impairs human brain tumor cell invasion in vitro and promotes apoptosis. Cancer Gene Ther 2003; 10:141-51; PMID:12536203; http://dx.doi.org/10.1038/sj.cgt.7700546